UBS Group
CRL icon

UBS Group’s Charles River Laboratories CRL Stock Holding History

UBS Group’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.86M Buy
+17,000
New +$3.03M ﹤0.01% 4432

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

UBS Group's CRL Position: Q2 2026 in Review

UBS Group reduced its Charles River Laboratories (CRL) stake by 12% in Q2 2026, selling an estimated $15.1M and leaving 646,747 shares worth $147M. The position accounts for 0.02% of the portfolio, ranked #868.

UBS Group first reported a position in CRL in Q4 2014 and has held it in 47 quarters since. The position peaked at $360M in Q1 2025. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • UBS Group held 646,747 shares of Charles River Laboratories worth $147M as of Q2 2026.
  • UBS Group sold 84,718 Charles River Laboratories shares in Q2 2026, an estimated $15.1M.
  • Charles River Laboratories made up 0.02% of UBS Group's portfolio in Q2 2026, its #868 holding.
  • UBS Group first reported a position in Charles River Laboratories in Q4 2014 and has held it in 47 quarters since.
  • UBS Group's Charles River Laboratories position peaked at $360M in Q1 2025.
  • 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.